These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 23836561)

  • 1. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
    Ravandi F; Jorgensen JL; Thomas DA; O'Brien S; Garris R; Faderl S; Huang X; Wen S; Burger JA; Ferrajoli A; Kebriaei P; Champlin RE; Estrov Z; Challagundla P; Wang SA; Luthra R; Cortes JE; Kantarjian HM
    Blood; 2013 Aug; 122(7):1214-21. PubMed ID: 23836561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
    Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
    Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study.
    Salah-Eldin M; Abousamra NK; Azzam H
    Med Oncol; 2014 May; 31(5):938. PubMed ID: 24692146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Short NJ; Jabbour E; Sasaki K; Patel K; O'Brien SM; Cortes JE; Garris R; Issa GC; Garcia-Manero G; Luthra R; Thomas D; Kantarjian H; Ravandi F
    Blood; 2016 Jul; 128(4):504-7. PubMed ID: 27235138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.
    Appelmann I; Rillahan CD; de Stanchina E; Carbonetti G; Chen C; Lowe SW; Sherr CJ
    Blood; 2015 Feb; 125(9):1444-51. PubMed ID: 25499760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
    Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
    Benjamini O; Dumlao TL; Kantarjian H; O'Brien S; Garcia-Manero G; Faderl S; Jorgensen J; Luthra R; Garris R; Thomas D; Kebriaei P; Champlin R; Jabbour E; Burger J; Cortes J; Ravandi F
    Am J Hematol; 2014 Mar; 89(3):282-7. PubMed ID: 24779033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
    de Labarthe A; Rousselot P; Huguet-Rigal F; Delabesse E; Witz F; Maury S; Réa D; Cayuela JM; Vekemans MC; Reman O; Buzyn A; Pigneux A; Escoffre M; Chalandon Y; MacIntyre E; Lhéritier V; Vernant JP; Thomas X; Ifrah N; Dombret H;
    Blood; 2007 Feb; 109(4):1408-13. PubMed ID: 17062730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy.
    Ohno R;
    Curr Hematol Malig Rep; 2006 Sep; 1(3):180-7. PubMed ID: 20425349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Daver N; Thomas D; Ravandi F; Cortes J; Garris R; Jabbour E; Garcia-Manero G; Borthakur G; Kadia T; Rytting M; Konopleva M; Kantarjian H; O'Brien S
    Haematologica; 2015 May; 100(5):653-61. PubMed ID: 25682595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.
    Strati P; Kantarjian H; Thomas D; O'Brien S; Konoplev S; Jorgensen JL; Luthra R; Abruzzo L; Jabbour E; Quintas-Cardama A; Borthakur G; Faderl S; Ravandi F; Cortes J
    Cancer; 2014 Feb; 120(3):373-80. PubMed ID: 24151050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
    Ottmann OG; Pfeifer H
    Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.
    Pane F; Cimino G; Izzo B; Camera A; Vitale A; Quintarelli C; Picardi M; Specchia G; Mancini M; Cuneo A; Mecucci C; Martinelli G; Saglio G; Rotoli B; Mandelli F; Salvatore F; Foà R;
    Leukemia; 2005 Apr; 19(4):628-35. PubMed ID: 15744351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).
    Scheuring UJ; Pfeifer H; Wassmann B; Bruck P; Atta J; Petershofen EK; Gehrke B; Gschaidmeier H; Hoelzer D; Ottmann OG
    Blood; 2003 Jan; 101(1):85-90. PubMed ID: 12393581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
    Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
    Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Jabbour E; Kantarjian HM; Aldoss I; Montesinos P; Leonard JT; Gómez-Almaguer D; Baer MR; Gambacorti-Passerini C; McCloskey J; Minami Y; Papayannidis C; Rocha V; Rousselot P; Vachhani P; Wang ES; Wang B; Hennessy M; Vorog A; Patel N; Yeh T; Ribera JM
    JAMA; 2024 Jun; 331(21):1814-1823. PubMed ID: 38722621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
    Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
    Scheuring UJ; Pfeifer H; Wassmann B; Brück P; Gehrke B; Petershofen EK; Gschaidmeier H; Hoelzer D; Ottmann OG
    Leukemia; 2003 Sep; 17(9):1700-6. PubMed ID: 12970767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.